Table 2 In-hospital outcomes of patients undergoing TAVR in the United States from 2016 to 2020

In-hospital mortality

3710 (1.3%)

2145 (1.1%)

1295 (1.6%)

270 (2.6%)

1.4 (1.2–1.7)

< 0.001

2.4 (1.8–3.3)

< 0.001

LOS, days (SEM)

3.8 (0.04)

3.3 (0.03)

4.6 (0.06)

6.9 (0.22)

N/A

< 0.001

N/A

< 0.001

Cardiovascular complications

Cardiac arrest

620 (0.2)

340 (0.2)

230 (0.3)

50 (0.5)

1.5 (1.0-2.1)

0.058

2.4 (1.2–4.9)

0.015

Cardiogenic shock

4010 (1.4)

2415 (1.3)

1305 (1.6)

290 (2.8)

1.2 (1.1–1.4)

0.009

2.0 (1.5–2.7)

< 0.001

Impella

880 (0.3)

450 (0.2)

355 (0.4)

75 (0.7)

1.8 (1.3–2.5)

< 0.001

1.9 (1.0-3.4)

0.035

Intraaortic balloon

1195 (0.4)

675 (0.4)

385 (0.5)

135 (1.3)

1.3 (0.9–1.7)

0.126

2.1 (1.3–3.3)

0.002

Procedural AMI

8655 (3.1)

5445 (2.9)

2645 (3.2)

565 (5.5)

1.1 (0.9–1.2)

0.329

1.7 (1.4–2.1)

< 0.001

Vascular access complications

10,235 (3.7)

6465 (3.5)

3300 (4.0)

470 (4.6)

1.2 (1.1–1.3)

0.003

1.3 (1.0-1.6)

0.043

Conversion to open heart surgery

960 (0.3)

675 (0.4)

240 (0.3)

45 (0.4)

0.9 (0.6–1.2)

0.384

1.3 (0.6–2.6)

0.479

Other complications

Post-operative infection

2350 (0.8)

1175 (0.6)

885 (1.1)

290 (2.8)

1.8 (1.5–2.2)

< 0.001

3.0 (2.2–4.1)

< 0.001

Respiratory complications

18,905 (6.8)

10,355 (5.5)

7010 (8.6)

1540 (15.1)

1.5 (1.4–1.6)

< 0.001

2.3 (2.0-2.6)

< 0.001

AKI

26,770 (9.6)

9340 (5.0)

17,340 (21.2)

N/A

5.0 (4.7–5.3)

< 0.001

N/A

N/A